THE EFFECTS OF SYNBIOTIC SUPPLEMENTATION ON BODY MASS INDEX, METABOLIC AND INFLAMMATORY BIOMARKERS, AND APPETITE IN PATIENTS WITH METABOLIC SYNDROME: A TRIPLE-BLIND RANDOMIZED CONTROLLED TRIAL

Background and Aim: It has been shown recently that metabolic syndrome is associated with gut dysbiosis. The gut microbiotamay be themain target for prevention or treatment ofmetabolic syndrome.We investigated the effects of symbiotic supplementation on metabolic syndrome.Methods: In this triple-blinded clinical trial, 46 Iranian patients with metabolic syndrome, from both sexes, aged 25–70 years, who fulfilled inclusion criteria were randomly categorized to receive either the synbiotic or a placebo capsule, twice a day for three months, plus a weight-loss diet using stratified random sampling based on body mass index (BMI). Each synbiotic capsule consisted of seven strains probiotic bacteria (2× 108) plus fructooligosaccharide as a prebiotic. Anthropometric measurements and biochemical tests were assessed at baseline and at the end of week 12 for fasting blood sugar (FBS), insulin, lipid profile, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1).Results: The mean changes of weight, BMI, FBS, insulin, homeostatic model assessment for insulin resistance (HOMA-IR), and GLP-1 between the two groups was statistically significant (p < .001). Furthermore, peptide YY (PYY) increased significantly in the synbiotic group (p .05). The trend of weight loss in the synbiotic group was significant until the end of the study (p < .001) while it stopped at week 6 in the placebo group.Conclusion: Synbiotic treatmentmay improve the status of BMI, FBS, insulin resistance, HOMA-IR, GLP-1, and PYY in patients with metabolic syndrome.

کلیدواژه ها:

appetite ، body mass index ، insulin resistance ، microflora ، synbiotic